Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes. - Wikidata - awgldk - TriplyDB

Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes.

Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes.

http://www.wikidata.org/entity/Q36094369

about

A lipid gate for the peripheral control of pain Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer Comparison of free serum oxylipin concentrations in hyper- vs. normolipidemic men Bioactive lipid profiling reveals drug target engagement of a soluble epoxide hydrolase inhibitor in a murine model of tobacco smoke exposure Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern Potent natural soluble epoxide hydrolase inhibitors from Pentadiplandra brazzeana baillon: synthesis, quantification, and measurement of biological activities in vitro and in vivo Peripheral gating of pain signals by endogenous lipid mediators.Arsenic induces diabetic effects through beta-cell dysfunction and increased gluconeogenesis in mice Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures.Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice.Effects of soluble epoxide hydrolase deficiency on acute pancreatitis in mice Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain.Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order Brassicales Metabolomics in diabetic complications.Fatting the brain: a brief of recent research Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie Targeted metabolomics of the arachidonic acid cascade: current state and challenges of LC-MS analysis of oxylipins.Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis.Modulation of the endogenous omega-3 fatty acid and oxylipin profile in vivo-A comparison of the fat-1 transgenic mouse with C57BL/6 wildtype mice on an omega-3 fatty acid enriched diet.Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase.Pharmacokinetics and antinociceptive effects of the soluble epoxide hydrolase inhibitor t-TUCB in horses with experimentally induced radiocarpal synovitis.Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice.Epoxy fatty acids mediate analgesia in murine diabetic neuropathy.Erectogenic and Aphrodisiac Property of Moringa oleifera: Involvement of Soluble Epoxide Hydrolase Enzyme.Comparison of sample preparation methods for the quantitative analysis of eicosanoids and other oxylipins in plasma by means of LC-MS/MS.CYP2J2 - regulation, function and polymorphism.

P2860

Q26995053-733AD2AC-B6CA-49BE-A8F1-AF2A203EB2F2 Q27684895-52264CF7-1F0A-47E2-B2C4-2FAAEF1DCAE0 Q28245279-A3201B4E-16DC-4F2B-8A8B-8AE4DE5E5F9F Q28248377-84E31B52-48B4-41F2-9D40-A340EEE62C4D Q28304230-FC72A588-CFEE-44A2-B022-A111F683D441 Q28387829-370E16DD-7F86-4DE7-9E52-5F419F78CDA7 Q28391885-E08B5DAD-B319-4A90-A56E-85A51E305872 Q28392212-A7F28F73-5E6B-46A7-B146-1FAE22A9EFB4 Q28392416-684B3AFC-1E85-4245-89B0-BF676675C745 Q28395323-6E63A694-D694-42A3-82C0-10A2A5A09AE8 Q28396233-A2601F67-B8FF-4E3A-B68B-7779705ABC39 Q28397238-5A8F74D3-A032-41F3-93F8-8BF8B32596BB Q28543232-6A83754C-99A9-418D-B25F-F2ABD1FCC4B3 Q33608432-A167D620-965E-4FA1-80BB-EC0187044E13 Q34447553-13F59775-7A98-4E15-8B8E-1F4FA8C06FE8 Q35069446-CE24E2A4-0238-4FDA-9082-233CBCAD7E50 Q35207683-319BA66E-72F5-4296-AF2F-F7F4CD0C4764 Q35427989-886FA957-E16C-4CF9-9797-811D6903D9FA Q35895730-4C7A18A6-F28B-4501-A1D9-A4095AF804F8 Q36362984-322F330D-D653-4172-A6D7-3AA3068DBDE8 Q37041169-62A06F4F-F3A7-409C-97D5-C5FED92ACD4A Q37155461-3B8ACFFD-C8C1-4F48-8CA3-B2BC56CB86C5 Q37250368-D20AFB44-5067-4081-A81F-92CD55783269 Q38313787-76D7CD81-F9B4-4DBE-A9C3-E9A569F8EB2E Q39392465-E0775892-96A9-486A-8CEA-2FFFB30B5D16 Q39659143-6E65E947-BA99-41E2-BC26-74298A96A44A Q40060262-5284F9F5-F658-4EBD-BFA8-B09643B0D564 Q46078832-079E840A-BA1C-4ECA-A875-DBC194C54E97 Q46415634-91C6D8A6-5871-46AE-A8E7-8A9DCE63C71C Q46614540-0C6B2E3A-02F8-4C4F-B3AF-1B975FA965C8 Q46708671-71CCEA82-B5B3-4B78-B9DB-8372920B4BB8 Q50915038-3AB3BFAA-77C7-4554-BE4D-18DE54C5D240 Q51022270-077E7128-A204-4D1C-BF6F-3812FFCE29D8 Q51709663-CFBE8323-151A-4A67-8CF6-69F6820941EE

P2860

Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes.

http://www.wikidata.org/entity/Q36094369

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Acute augmentation of epoxygen ...... rat model of type I diabetes.

@ast

Acute augmentation of epoxygen ...... rat model of type I diabetes.

@en

type

label

Acute augmentation of epoxygen ...... rat model of type I diabetes.

@ast

Acute augmentation of epoxygen ...... rat model of type I diabetes.

@en

prefLabel

Acute augmentation of epoxygen ...... rat model of type I diabetes.

@ast

Acute augmentation of epoxygen ...... rat model of type I diabetes.

@en

P1433

Q36094369-85CC84BB-BE23-40A8-B2EE-7E31131AB0B8

P1476

Q36094369-12CCE238-F715-460E-ACCC-3BDC055C641F

P2093

Q36094369-0EB67DAF-61B5-4F5F-B7B8-F0E9A005E642

Q36094369-1CFABD80-EBB3-490A-ADC6-B576B32D55DF

Q36094369-8DD0E0B6-87F2-47A3-9CF7-F6D231735FD5

Q36094369-AC35C6CC-9FEB-4E95-A4EA-BBDC64C68FC1

Q36094369-D1330B68-C85E-4EE5-A60A-45DE7AA385FB

Q36094369-EE39F707-5E56-471D-92D7-7365DE32D728

Q36094369-F7E90C09-0D7E-4DEC-8CF7-AC13B8E775AE

P2860

Q36094369-0941748A-D922-47A6-80BD-F8BEB3E6C2C8

Q36094369-12D00433-8A16-43B2-8EC0-8505DECB7D50

Q36094369-18F32216-6803-4700-8D61-119A6257676D

Q36094369-1AD79A61-87F6-4CE4-A09A-61121BF05E65

Q36094369-217B5664-C3AC-42BB-82B4-1E449DA483E0

Q36094369-2EE7CB28-50EF-40BE-9026-4E42E93FF3FA

Q36094369-47CA60A5-A902-4DB0-A21C-2B4026FDC1A4

Q36094369-65AF3732-EB60-41D2-B6E8-0ED4D8AAB505

Q36094369-696AB23F-BAC8-4254-840E-5F9FD3450BAD

Q36094369-71CD83BB-E8DB-40D7-B68E-39E679AD069E

P304

Q36094369-8E16B37F-8CC9-4FE1-907B-ED5876298FC3

P31

Q36094369-EEA89F0D-2AE2-4657-BF87-0426DCD02779

P356

Q36094369-B7A28CF9-A942-4C31-8047-0984F0CB64E2

P407

Q36094369-EE38E4BF-9CB7-450D-B49D-8F4AE997F12D

P433

Q36094369-9CEC16D7-C8BA-4EAD-8F5E-6F544D7D1574

P478

Q36094369-B3718B00-910C-4992-9F2D-EFF10B8FBBA7

P50

Q36094369-3DC713DF-F6AC-415B-A39F-E6315D14744F

Q36094369-88D96ABB-61C6-4546-B296-01EC522DD5BB

P577

Q36094369-03139E38-10A9-48DE-A5D8-08ADBB5395BD

P5875

Q36094369-24707603-5874-4077-8F48-F5C7ADE86199

P698

Q36094369-75E52849-B6BC-4803-970A-4D570733E6E6

P921

Q36094369-B8AB7F13-45B1-45FB-A5FC-D41D1D2CB13C

Q36094369-D39B9B1B-3B1F-4321-BE89-038FFDA03940

P932

Q36094369-4B2561FF-7FE3-4F7D-96E5-930A3754339A

P356

PNAS.1208708109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Acute augmentation of epoxygen ...... a rat model of type I diabetes

@en

P2093

Ahmed Bettaieb

http://www.w3.org/2001/XMLSchema#string

Bruce D Hammock

http://www.w3.org/2001/XMLSchema#string

Christophe Morisseau

http://www.w3.org/2001/XMLSchema#string

Fawaz G Haj

http://www.w3.org/2001/XMLSchema#string

Karen M Wagner

http://www.w3.org/2001/XMLSchema#string

Nils H Schebb

http://www.w3.org/2001/XMLSchema#string

Sung Hee Hwang

http://www.w3.org/2001/XMLSchema#string

P2860

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin

Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance

Epoxyeicosanoid signaling in CNS function and disease

Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model

Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain

Soluble epoxide hydrolase is a therapeutic target for acute inflammation

Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies.

Diabetic neuropathy: mechanisms to management

P304

11390-11395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1208708109

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228066999

http://www.w3.org/2001/XMLSchema#string

P698

22733772

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3396532

http://www.w3.org/2001/XMLSchema#string